TCI Wealth Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-169
Closed -$5K 2476
2022
Q1
$5K Buy
+169
New +$4.58K ﹤0.01% 1589
2021
Q4
Sell
-70
Closed -$3K 2484
2021
Q3
$3K Buy
70
+15
+27% +$590 ﹤0.01% 1996
2021
Q2
$2K Buy
55
+7
+15% +$264 ﹤0.01% 2077
2021
Q1
$2K Buy
+48
New +$1.9K ﹤0.01% 1868

Other funds holding RIGL

TCI Wealth Advisors's RIGL Position: Q2 2022 in Review

TCI Wealth Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 169 shares — an estimated $5K sold.

TCI Wealth Advisors first reported a position in RIGL in Q1 2021 and held it in 4 quarters. The position peaked at $5K in Q1 2022. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

  • TCI Wealth Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 169 Rigel Pharmaceuticals shares in Q2 2022, an estimated $5K.
  • TCI Wealth Advisors first reported a position in Rigel Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • TCI Wealth Advisors's Rigel Pharmaceuticals position peaked at $5K in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on TCI Wealth Advisors's 13F filing for Q2 2022, filed 19 Jul 2022.